Domschke Christoph, Schneeweiss Andreas, Stefanovic Stefan, Wallwiener Markus, Heil Joerg, Rom Joachim, Sohn Christof, Beckhove Philipp, Schuetz Florian
Department of Gynecology and Obstetrics, Heidelberg University Hospital, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Regensburg Center for Interventional Immunology (RCI) and University Medical Center of Regensburg, Regensburg, Germany.
Breast Care (Basel). 2016 Apr;11(2):102-7. doi: 10.1159/000446061. Epub 2016 Apr 27.
More recently, immunotherapy has emerged as a novel potentially effective therapeutic option also for solid malignancies such as breast cancer (BC). Relevant approaches, however, are determined by the 2 main elements of cancer immunoediting - the elimination of nascent transformed cells by immunosurveillance on the one hand and tumor immune escape on the other hand. Correspondingly, we here review the role of the various cellular immune players within the host-protective system and dissect the mechanisms of immune evasion leading to tumor progression. If the immune balance of disseminated BC cell dormancy (equilibrium phase) is lost, distant metastatic relapse may occur. The relevant cellular antitumor responses and translational immunotherapeutic options will also be discussed in terms of clinical benefit and future directions in BC management.
最近,免疫疗法也已成为一种新型的、对乳腺癌(BC)等实体恶性肿瘤可能有效的治疗选择。然而,相关方法取决于癌症免疫编辑的两个主要因素——一方面是通过免疫监视消除新生的转化细胞,另一方面是肿瘤免疫逃逸。相应地,我们在此回顾宿主保护系统中各种细胞免疫参与者的作用,并剖析导致肿瘤进展的免疫逃逸机制。如果播散性BC细胞休眠(平衡期)的免疫平衡丧失,可能会发生远处转移复发。还将从临床益处和BC管理的未来方向方面讨论相关的细胞抗肿瘤反应和转化免疫治疗选择。